Tags

Type your tag names separated by a space and hit enter

Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Nephrol Dial Transplant. 2005 Oct; 20(10):2186-93.ND

Abstract

BACKGROUND

Patients with secondary hyperparathyroidism often require therapy that provides long-term control of parathyroid hormone concentrations without increasing calcium and phosphorus concentrations. Cinacalcet modulates the calcium-sensing receptor on the parathyroid gland to reduce secretion of parathyroid hormone and lower serum calcium, phosphorus and calcium-phosphorus product in haemodialysis patients.

METHODS

Dialysis patients with secondary hyperparathyroidism [parathyroid hormone (PTH) level > or =300 pg/ml] who were enrolled in one of four phase 2 placebo-controlled studies were eligible to enroll in an open-label extension study in which all patients received cinacalcet. For this extension study, cinacalcet was initiated at 30 mg in all patients and the dose was escalated to a maximum of 180 mg once daily if PTH concentrations were >250 pg/ml. Use of concomitant vitamin D sterols and phosphate binders was not restricted.

RESULTS

The analysis of all patients (n = 59) completing 100 weeks of cinacalcet treatment showed long-term control of PTH and calcium-phosphorus product. Approximately 55% achieved a PTH concentration < or =300 pg/ml at the week-100 study visit, and approximately 60% had at least a 30% reduction in PTH from baseline. Serum calcium, phosphorus and the calcium-phosphorus product did not increase during the study. Concomitant vitamin D sterol and phosphate binder therapy remained stable. Cinacalcet was safe and generally well tolerated at doses up to 180 mg/day.

CONCLUSIONS

In this long-term study, cinacalcet effectively sustained reductions in PTH for up to 3 years without increasing concentrations of serum calcium, phosphorus or calcium-phosphorus product.

Authors+Show Affiliations

Indiana University Department of Medicine, 1001 West 10th Street, OPW 526, Indianapolis, IN 46202, USA. smoe@iupui.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Clinical Trial, Phase II
Journal Article

Language

eng

PubMed ID

16030053

Citation

Moe, Sharon M., et al. "Long-term Treatment of Secondary Hyperparathyroidism With the Calcimimetic Cinacalcet HCl." Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, vol. 20, no. 10, 2005, pp. 2186-93.
Moe SM, Cunningham J, Bommer J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005;20(10):2186-93.
Moe, S. M., Cunningham, J., Bommer, J., Adler, S., Rosansky, S. J., Urena-Torres, P., Albizem, M. B., Guo, M. D., Zani, V. J., Goodman, W. G., & Sprague, S. M. (2005). Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, 20(10), 2186-93.
Moe SM, et al. Long-term Treatment of Secondary Hyperparathyroidism With the Calcimimetic Cinacalcet HCl. Nephrol Dial Transplant. 2005;20(10):2186-93. PubMed PMID: 16030053.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. AU - Moe,Sharon M, AU - Cunningham,John, AU - Bommer,Jürgen, AU - Adler,Stephen, AU - Rosansky,Steven J, AU - Urena-Torres,Pablo, AU - Albizem,Moetaz B, AU - Guo,Matthew D, AU - Zani,Valter J, AU - Goodman,William G, AU - Sprague,Stuart M, Y1 - 2005/07/19/ PY - 2005/7/21/pubmed PY - 2005/12/13/medline PY - 2005/7/21/entrez SP - 2186 EP - 93 JF - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association JO - Nephrol. Dial. Transplant. VL - 20 IS - 10 N2 - BACKGROUND: Patients with secondary hyperparathyroidism often require therapy that provides long-term control of parathyroid hormone concentrations without increasing calcium and phosphorus concentrations. Cinacalcet modulates the calcium-sensing receptor on the parathyroid gland to reduce secretion of parathyroid hormone and lower serum calcium, phosphorus and calcium-phosphorus product in haemodialysis patients. METHODS: Dialysis patients with secondary hyperparathyroidism [parathyroid hormone (PTH) level > or =300 pg/ml] who were enrolled in one of four phase 2 placebo-controlled studies were eligible to enroll in an open-label extension study in which all patients received cinacalcet. For this extension study, cinacalcet was initiated at 30 mg in all patients and the dose was escalated to a maximum of 180 mg once daily if PTH concentrations were >250 pg/ml. Use of concomitant vitamin D sterols and phosphate binders was not restricted. RESULTS: The analysis of all patients (n = 59) completing 100 weeks of cinacalcet treatment showed long-term control of PTH and calcium-phosphorus product. Approximately 55% achieved a PTH concentration < or =300 pg/ml at the week-100 study visit, and approximately 60% had at least a 30% reduction in PTH from baseline. Serum calcium, phosphorus and the calcium-phosphorus product did not increase during the study. Concomitant vitamin D sterol and phosphate binder therapy remained stable. Cinacalcet was safe and generally well tolerated at doses up to 180 mg/day. CONCLUSIONS: In this long-term study, cinacalcet effectively sustained reductions in PTH for up to 3 years without increasing concentrations of serum calcium, phosphorus or calcium-phosphorus product. SN - 0931-0509 UR - https://www.unboundmedicine.com/medline/citation/16030053/Long_term_treatment_of_secondary_hyperparathyroidism_with_the_calcimimetic_cinacalcet_HCl_ L2 - https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/gfh966 DB - PRIME DP - Unbound Medicine ER -